Clinical Trial Update: Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SNA-120 for pruritus and psoriasis in patients treated with calcipotriene, focusing on safety, tolerability, and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pruritus
• Psoriasis

Drugs mentioned

• SNA-120

Snippet

Sponsor: Sienna Biopharmaceuticals | Conditions: Pruritus, Psoriasis | Phase 2 | Status: COMPLETED